Clinical trials located in

Oulu

Oulu city is located in Finland. Currently, 15 clinical trials are being conducted in this city.

Oulu, located in northern Finland, is a vibrant city known for its technology-driven economy, particularly in IT and communications. It hosts the annual Air Guitar World Championship, showcasing its quirky side. The city is also a gateway to exploring the Arctic, with its unique blend of modern urban life and close proximity to nature. Oulu’s market square, with the iconic Policeman statue, and the Hupisaaret City Park, are among its notable attractions. The Oulu Cathedral and the Tietomaa Science Center reflect the city’s rich cultural and educational heritage.

  • CT-EU-00038483

    Testing new immunotherapy combinations for non-small-cell lung cancer

    This study is testing a new treatment for non-small cell lung cancer that has not yet been treated with drugs. In the study, researchers will look at the effects of combining different immunotherapy drugs and their safety and effectiveness in treating cancer. Participants will receive various combinations of the drugs pembrolizumab, dostarlimab, belrestotug and GSK6097608. The study will last several years and will monitor the effects of different drug combinations and any potential side effects. The study aims to find new ways to treat lung cancer with fewer negative side effects.

    BelgiumFinlandFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Study on new immunotherapy combinations for untreated advanced lung cancer

    This is a study of patients whose non-small cell lung cancer is at an advanced stage (cannot be cured by surgery or has spread to other parts of the body) and has not been previously treated. The study will test new combinations of immunotherapy (drugs that support the immune system in the fight against cancer) and compare them with a single immunotherapy drug. Scientists want to find out how well these combinations work and how safe they are. The study will also look at how the body processes these drugs. The drugs used in this study are called Belrestoug, GSK4428859A and EOS884448, but these names all refer to the same drug. Scientists will measure the effectiveness of the drugs by looking at how many patients have their cancer shrink and how long it takes for the cancer to start growing again or before the patient dies. They will also record any side effects that may occur during the study and for 90 days after the last treatment dose.

    BelgiumFinlandFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Exploring treatment options for newly diagnosed Multiple Myeloma

    This clinical trial investigates two treatment paths for newly diagnosed multiple myeloma patients who are not planned for stem cell transplant initially. The first group receives a combination of bortezomib, lenalidomide, and dexamethasone (VRd) followed by cilta-cel, an innovative therapy. The second group receives VRd followed by continued treatment with lenalidomide and dexamethasone (Rd). The study evaluates the effectiveness of these treatments by monitoring disease progression, treatment response, and patient survival rates. It also assesses the safety and side effects of the treatments, aiming to improve the quality of life and outcomes for patients with multiple myeloma. The trial’s objective is to provide valuable data on the potential benefits of integrating cilta-cel in the treatment regimen, compared to the more traditional approach, offering insights for better management of this challenging cancer.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyGreeceHungaryNetherlandsNorwayPolandSwedenUnited Kingdom
  • Study investigating new medicine for advanced metastatic breast cancer

    A clinical study is investigating the impact and safety of a new medicine named ARV-471 (Vepdegrestrant), contrasting its effects with an already-used drug called fulvestrant (FUL). This research targets individuals suffering from advanced metastatic breast cancer, a disease that often spreads to various parts of the body and is challenging to control. ARV-471 will be given to half of the participants, with the other half receiving fulvestrant. The effects of both will be monitored over time. ARV-471 is consumed by mouth, while FUL is administered through injections.

    BelgiumBulgariaCzechiaFinlandFranceGermanyGreeceHungaryItalyNorwayPolandSlovakiaSpainSwedenUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Testing drug combinations in recurring multiple myeloma

    This is a type of research study where the researchers compare two different treatments for multiple myeloma, a type of cancer in your blood. In the study, people will be placed into different groups and receive either a combination of iberdomide, daratumumab, and dexamethasone, or another combination of daratumumab, bortezomib, and dexamethasone. The researchers want to check how well the cancer responds to these treatments and see which one works better.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyGreeceItalyNetherlandsNorwayPolandPortugalSpainSwedenUnited Kingdom
  • Radium-223 radiation vs. new hormone therapy in prostate cancer trial

    In this study, scientists are looking into two treatments for prostate cancer that has spread to the bone. One is a medicine called Radium-223 Dichloride or simply Xofigo which uses radiation to destroy cancer cells. The other is a new kind of treatment that stops hormones from working, as these hormones can sometimes help cancer grow. This new treatment is called Novel Anti-hormonal Therapy or NAH for short. The aim is to see which works better and to compare their safety profiles. Xofigo works by emitting a special type of radiation once it is injected into the body and absorbed by the bones. This radiation travels only a short distance, so it doesn’t harm healthy cells while killing cancerous ones. NAH, on the other hand, includes medications like abiraterone acetate (Zytiga) or enzalutamide (Xtandi) which are usually given to advanced prostate cancer patients. People taking part in this study will either receive Xofigo or NAH. Xofigo is given via an injection into a vein every 4 weeks for up to 6 months, while an oral form of NAH will be given daily until the disease progresses. Participants will be in this study for around 2 years, visiting the hospital or clinic every 2 weeks initially and then less often. There will be blood and urine tests and questionnaires about well-being and pain management.

    AustriaCzechiaFinlandFranceGermanyHungaryItalyPolandSpainUnited Kingdom
  • Impact of apalutamide on hormone-sensitive prostate cancer

    This is a study on prostate cancer, particularly patients suffering from a high-risk, hormone-sensitive form. The researchers want to check how adding a drug called apalutamide to the regular treatment can affect the cancer. The standard treatment includes radiotherapy and a drug that blocks the hormone responsible for cancer growth, known as LHRH. This study will check if adding apalutamide can delay the cancer from spreading or help patients live longer. The researchers will track disease progress using a special imaging test called PSMA-PET. They will also monitor changes in PSA, a protein made by the prostate that rises when cancer is present. Other important measures include how long it takes for the cancer to spread and the general rate of survival.

    AustriaBelgiumCzechiaDenmarkFinlandGermanyHungaryItalyPolandPortugalSlovakiaSpainSweden
  • Comparing darolutamide with standard therapy in hormone sensitive prostate cancer

    This study explores a combination therapy using darolutamide and androgen deprivation therapy (ADT) for men with high-risk biochemical recurrence of prostate cancer. ADT are treatments that block androgens production in the body. The trial aims to determine if this combination prolongs the time without cancer worsening or leading to death compared to ADT alone. Participants will be randomly assigned to receive either the combination treatment or a placebo with ADT for 24 months. The study will track cancer progression, overall health, and any side effects, offering potential advancements in prostate cancer treatment.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Studying safety & efficacy of new drug for early Alzheimer’s

    This study involves a new drug called AL-101(Alector) (GSK4527226). It is intended for people suffering from the early stage of Alzheimer’s disease. We will give some people with Alzheimer’s disease a drug and others a neutral drug (placebo). Scientists want to see if the new drug is better. Doctors use scoring systems to check a drug’s effectiveness. One way is through the CDR-SB score, which tests things like memory or problem-solving. Patients must score from 0 to 18 points. Higher scores mean they have more difficulties. Another way to check it is iADRS – it is a composite score that measures cognitive properties and functions. It is a combination of two tests called ADAS-Cog14 and ADCS-iADL. They test your thinking ability and ability to perform everyday activities. Higher scores mean they have more problems. Doctors also use ADAS-Cog14, ADCS-ADL-MCI, and ADCS-iADL separately to check for the same things, and ADCOMS to see how brain function changes over time.

    FinlandFranceGermanyItalyNetherlandsNorwaySpainSwedenUnited Kingdom
  • CT-EU-00036742

    Monitoring RSV vaccine safety in post-vaccination pregnancies

    This study tracks the safety of the RSVPreF3 vaccine in women who had it during previous pregnancies. It’s focused on women who are pregnant again after receiving the vaccine and will assess the health of both mothers and their babies. The study’s main aim is to understand any potential impacts of the vaccine on pregnancy outcomes and infant health. This research is important as it provides vital information on the safety of RSV vaccines in pregnant women, contributing to public health knowledge.

    BelgiumFinlandFranceGermanyItalySpain
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain

See more clinical trials in other cities in Finland:

.